Avenda Health, an AI healthcare company, announced the Centers for Medicare & Medicaid Services has assigned a national payment rate for the company’s innovative prostate cancer mapping technology, Unfold AI.Â
Unfold AI is better at identifying cancer margins in the prostate than physicians identifying margins by sight, according to a new study. This AI improves accuracy from 67% to 84%, giving physicians more clarity and treatment planning, allowing them to better recommend therapies tailored to each patient.
Exscientia plc announced it will be expanding its work with Amazon Web Services to use the cloud provider’s artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation.
Merck Global Health Innovation Fund has made a strategic investment into Qure.ai as part of its Series D round.Â
A computer program based on data from nearly a half-million tissue images and powered by artificial intelligence can accurately diagnose cases of adenocarcinoma, the most common form of lung cancer, a study published June 11 in Nature Communications shows.Â
Investigators from UCLA Health found using artificial intelligence to help map out the boundaries of cancerous prostate tissue can significantly reduce the risk of underestimating the extent of prostate cancer—an advancement that can help ensure an accurate diagnosis, precise treatment planning and effective surgical procedures.
Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, has released results from its latest clinical trial demonstrating the superior performance of their HelioLiver Dx test compared to ultrasound.Â
In May, the American Society of Clinical Oncology released guidelines on the use of germline genetic testing panels in concert with tumor testing for cancer patients.1Â
COTA, PreciseDx, and Baptist Health South Florida announced a collaboration to assess and validate the performance of the artificial intelligence-enabled PreciseBreast test that predicts the likelihood of invasive breast cancer recurrence.
The UCSF Division of Clinical Informatics and Digital Transformation and UCSF Health have received a $5 million gift from Ken and Kathy Hao to develop a cutting-edge, real-time, continuous, and automated artificial intelligence monitoring platform for clinical care.
